1-I bought more shares yesterday 31K at .075! 2
Post# of 72447
(Total Views: 792)
Posted On: 11/12/2021 4:50:34 AM
1-I bought more shares yesterday 31K at .075!
2-I remain long since 2011 the stk,Ive traded the stk to lower my NCPS...
I was in IPIX when it was called Polymedix and U of Penn docs ran the show, poorly imo...great sci guys, lousy businessmen!
3-They sold the Co in bkrpsy court to Leo who stole the assets for $5m!
4-Leo ran the Co on a shoestring for years, cash is still an issue, Aspire funds the Co, but he remains committed thru thick and thin, overall I think hes "On Point"!
5-Ever since the 2017 SA article by MAKO this stock has been under pressure..https://seekingalpha.com/article/4081348-innovation-pharmaceuticals-cellceutix-still-hopeless-still-worthless
6-One by one Leo has tried to get the ball rolling w/ Prurisol, Kevitrin and Brilacidin! BRIL has exc oppy still in IBD, OM rinse in Cancers, etc.That data is ongoing and will eventually pan out w/ the italian partner!
7-Covid 19..what a great oppy this has been and is NOT over...we have now studied BRIL in serious,compromised pats in the hospital..ok the trial on face value show no bene but we need to read the fine print..before I thrown in the towel I want to see all these trial outcomes...
Other Outcome Measures
Duration of hospitalization [ Time Frame: Day 1 through Day 29 ]
Measured in days
Time to discharge [ Time Frame: Day 1 through Day 29 ]
Measured in days
Duration of invasive mechanical ventilation [ Time Frame: Day 1 through Day 29 ]
Measured in days (if applicable)
Duration of supplemental oxygen support [ Time Frame: Day 1 through Day 29 ]
Measured in days (if applicable)
Duration of extracorporeal membrane oxygenation (ECMO) [ Time Frame: Day 1 through Day 29 ]
Measured in days (if applicable)
Proportion of subjects with no oxygen therapy (and/or peripheral oxygen saturation SpO2 > 93% on room air) [ Time Frame: Day 8, Day 15, Day 29 ]
Subjects not using supplemental oxygen
Subject 28-day mortality [ Time Frame: Day 1 through Day 29 ]
Incidence of death
Change from baseline in disease biomarkers [ Time Frame: Day 1 through Day 29 ]
Concentrations of C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH), D-dimer, troponin hs, absolute neutrophil count
Change from baseline in inflammatory cytokines [ Time Frame: Day 1 through Day 15 ]
Concentrations of interleukin (IL)-1β, IL-6, IL-10, total IL-18, tumor necrosis factor (TNF)-α
Change from baseline in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) viral load [ Time Frame: Day 1 through Day 29 ]
Concentrations of SARS-CoV-2 from nasopharyngeal (or oropharyngeal) samples
Brilacidin measurements [ Time Frame: Day 1 through Day 4 ]
Concentrations of Brilacidin from plasma samples
8-I also want to know ""Heparin"" use in this trial..we know that Blood Clotting is an issue particularly in serious hospitalized pats..HEP is often used prophylactically in people admitted wher risk of stroke, clotting is prevalent...so who got Heparin or other Blood thinners is importnat to know..we know that giving HEP is a no no w/ BRIL and that BRIL actually binds to the Heparin sites in vitro so to me this is key!
9-Going forward its unlikely we see BRIL moving forward in any FU trial in Hospitalized Pats w/Covid, but I could see a FU trial being done w/ a partnered GILD and I would think they would want to do it..we now have data suggesting Remdesivir patient driven resistance is out there...https://www.news-medical.net/news/20211110/First-detection-of-SARS-CoV-2-remdesivir-resistance-in-an-immunocompromised-patient.aspx...what does this mean to IPIX when we know BRIL synergies Remdesivir and increases its sensitivity..stay tuned! This could be funded entirely by GILD and done quickly to gain an IND!
10-BRIL in OM (oral mucositis) is a shoe in IND and should be accelerated to approval..its a huge $2B market, Leo knows this and its Untapped!
11-BRIL is multi valent against many Virus in vitro..many labs are testing efficacy now...https://repository.arizona.edu/handle/10150/661245 UA has established Hep binding w/ BRIL...<LF and brilacidin inhibits viral attachment and the inhibition was diminished in the presence of heparin; 3) heparin decreased the potency of LF and brilacidin in cell culture. These studies support the translational potential of LF and brilacidin as broad-spectrum antivirals for coronaviruses including SARS-CoV-2.>..this is key going forward...one can NOT use HEP which is given like water on admission to hospitals because of stasis risk and clotting...its a NO NO w/ BRIL!
*****Again I want to know WHO got HEParin in our P-2 trial?*****
Finally w/ all we have going w/ BRIL just in Viral Infections, and eventually I think Kevetrin too..one would be FOOLISH to throw in the towel w/ IPIX..I remain LONG, the sp will creep back up into the mid .20s again and w/ any partnerring deals beyond Alpha Sigma...https://www.globenewswire.com/en/news-release/2019/07/22/1885838/0/en/Innovation-Pharmaceuticals-Announces-License-Agreement-with-Alfasigma-S-p-A-for-the-Development-and-Commercialization-of-Brilacidin-in-Ulcerative-Proctitis-Ulcerative-Proctosigmoid.html we stand to take advantage imo in the very large OTC outpatient Covid/other cold virus markets w/ an INHALER...imo this is clearly our NEW direction!
my best to all longs!
RP
2-I remain long since 2011 the stk,Ive traded the stk to lower my NCPS...
I was in IPIX when it was called Polymedix and U of Penn docs ran the show, poorly imo...great sci guys, lousy businessmen!
3-They sold the Co in bkrpsy court to Leo who stole the assets for $5m!
4-Leo ran the Co on a shoestring for years, cash is still an issue, Aspire funds the Co, but he remains committed thru thick and thin, overall I think hes "On Point"!
5-Ever since the 2017 SA article by MAKO this stock has been under pressure..https://seekingalpha.com/article/4081348-innovation-pharmaceuticals-cellceutix-still-hopeless-still-worthless
6-One by one Leo has tried to get the ball rolling w/ Prurisol, Kevitrin and Brilacidin! BRIL has exc oppy still in IBD, OM rinse in Cancers, etc.That data is ongoing and will eventually pan out w/ the italian partner!
7-Covid 19..what a great oppy this has been and is NOT over...we have now studied BRIL in serious,compromised pats in the hospital..ok the trial on face value show no bene but we need to read the fine print..before I thrown in the towel I want to see all these trial outcomes...
Other Outcome Measures
Duration of hospitalization [ Time Frame: Day 1 through Day 29 ]
Measured in days
Time to discharge [ Time Frame: Day 1 through Day 29 ]
Measured in days
Duration of invasive mechanical ventilation [ Time Frame: Day 1 through Day 29 ]
Measured in days (if applicable)
Duration of supplemental oxygen support [ Time Frame: Day 1 through Day 29 ]
Measured in days (if applicable)
Duration of extracorporeal membrane oxygenation (ECMO) [ Time Frame: Day 1 through Day 29 ]
Measured in days (if applicable)
Proportion of subjects with no oxygen therapy (and/or peripheral oxygen saturation SpO2 > 93% on room air) [ Time Frame: Day 8, Day 15, Day 29 ]
Subjects not using supplemental oxygen
Subject 28-day mortality [ Time Frame: Day 1 through Day 29 ]
Incidence of death
Change from baseline in disease biomarkers [ Time Frame: Day 1 through Day 29 ]
Concentrations of C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH), D-dimer, troponin hs, absolute neutrophil count
Change from baseline in inflammatory cytokines [ Time Frame: Day 1 through Day 15 ]
Concentrations of interleukin (IL)-1β, IL-6, IL-10, total IL-18, tumor necrosis factor (TNF)-α
Change from baseline in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) viral load [ Time Frame: Day 1 through Day 29 ]
Concentrations of SARS-CoV-2 from nasopharyngeal (or oropharyngeal) samples
Brilacidin measurements [ Time Frame: Day 1 through Day 4 ]
Concentrations of Brilacidin from plasma samples
8-I also want to know ""Heparin"" use in this trial..we know that Blood Clotting is an issue particularly in serious hospitalized pats..HEP is often used prophylactically in people admitted wher risk of stroke, clotting is prevalent...so who got Heparin or other Blood thinners is importnat to know..we know that giving HEP is a no no w/ BRIL and that BRIL actually binds to the Heparin sites in vitro so to me this is key!
9-Going forward its unlikely we see BRIL moving forward in any FU trial in Hospitalized Pats w/Covid, but I could see a FU trial being done w/ a partnered GILD and I would think they would want to do it..we now have data suggesting Remdesivir patient driven resistance is out there...https://www.news-medical.net/news/20211110/First-detection-of-SARS-CoV-2-remdesivir-resistance-in-an-immunocompromised-patient.aspx...what does this mean to IPIX when we know BRIL synergies Remdesivir and increases its sensitivity..stay tuned! This could be funded entirely by GILD and done quickly to gain an IND!
10-BRIL in OM (oral mucositis) is a shoe in IND and should be accelerated to approval..its a huge $2B market, Leo knows this and its Untapped!
11-BRIL is multi valent against many Virus in vitro..many labs are testing efficacy now...https://repository.arizona.edu/handle/10150/661245 UA has established Hep binding w/ BRIL...<LF and brilacidin inhibits viral attachment and the inhibition was diminished in the presence of heparin; 3) heparin decreased the potency of LF and brilacidin in cell culture. These studies support the translational potential of LF and brilacidin as broad-spectrum antivirals for coronaviruses including SARS-CoV-2.>..this is key going forward...one can NOT use HEP which is given like water on admission to hospitals because of stasis risk and clotting...its a NO NO w/ BRIL!
*****Again I want to know WHO got HEParin in our P-2 trial?*****
Finally w/ all we have going w/ BRIL just in Viral Infections, and eventually I think Kevetrin too..one would be FOOLISH to throw in the towel w/ IPIX..I remain LONG, the sp will creep back up into the mid .20s again and w/ any partnerring deals beyond Alpha Sigma...https://www.globenewswire.com/en/news-release/2019/07/22/1885838/0/en/Innovation-Pharmaceuticals-Announces-License-Agreement-with-Alfasigma-S-p-A-for-the-Development-and-Commercialization-of-Brilacidin-in-Ulcerative-Proctitis-Ulcerative-Proctosigmoid.html we stand to take advantage imo in the very large OTC outpatient Covid/other cold virus markets w/ an INHALER...imo this is clearly our NEW direction!
my best to all longs!
RP
(4)
(0)